cis-platinum_ototoxicity_in_children._Despite_the_recognized_ototoxicity_of_cis-platinum,_a_clinical_outline_for_the_audiologic_evaluation_of_patients_receiving_this_drug_has_not_been_clearly_defined._In_a_practical_approach_to_this_problem,_the_audiograms_of_48_pediatric_patients_referred_for_monitoring_during_planned_cis-platinum_therapy_were_reviewed._Eleven_patients_tested_with_auditory_brain-stem_response_(ABR)_audiometry_demonstrated_several_limitations_of_this_modality._Fourteen_children_underwent_initial_ABR_testing_followed_by_at_least_two_pure-tone_audiograms._The_remaining_23_patients_had_their_hearing_evaluated_by_pure-tone_audiometry_only._Various_factors_such_as_patient_age,_cis-platinum_dosage,_and_cranial_radiation_exposure_were_analyzed_for_apparent_effect._Younger_patients_tended_to_be_more_susceptible_to_audiologic_changes_with_the_administration_of_cis-platinum._The_proportion_of_patients_who_demonstrated_a_hearing_loss_increased_with_successive_dosing_as_did_the_severity_of_the_hearing_loss._Prior_exposure_to_cranial_radiation_was_strongly_linked_to_the_development_of_hearing_loss_following_cis-platinum_therapy._Guidelines_are_presented_regarding_the_use_of_clinical_audiometry_in_the_screening_of_these_pediatric_oncology_patients.